HomeCompareBPTSY vs EPRT

BPTSY vs EPRT: Dividend Comparison 2026

BPTSY yields 444.44% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPTSY wins by $25001.18M in total portfolio value
10 years
BPTSY
BPTSY
● Live price
444.44%
Share price
$0.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25001.24M
Annual income
$17,330,574,692.45
Full BPTSY calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — BPTSY vs EPRT

📍 BPTSY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTSY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPTSY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTSY
Annual income on $10K today (after 15% tax)
$37,777.78/yr
After 10yr DRIP, annual income (after tax)
$14,730,988,488.58/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, BPTSY beats the other by $14,730,977,293.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTSY + EPRT for your $10,000?

BPTSY: 50%EPRT: 50%
100% EPRT50/50100% BPTSY
Portfolio after 10yr
$12500.65M
Annual income
$8,665,293,931.65/yr
Blended yield
69.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BPTSY
No analyst data
Altman Z
-15.8
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTSY buys
0
EPRT buys
0
No recent congressional trades found for BPTSY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSYEPRT
Forward yield444.44%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$25001.24M$64.3K
Annual income after 10y$17,330,574,692.45$13,170.85
Total dividends collected$24314.87M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BPTSY vs EPRT ($10,000, DRIP)

YearBPTSY PortfolioBPTSY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$55,144$44,444.44$11,212$512.01+$43.9KBPTSY
2$288,057$229,052.73$12,689$692.09+$275.4KBPTSY
3$1,426,445$1,118,223.95$14,521$944.30+$1.41MBPTSY
4$6,701,426$5,175,129.87$16,841$1,302.88+$6.68MBPTSY
5$29,892,686$22,722,160.11$19,841$1,821.64+$29.87MBPTSY
6$126,709,939$94,724,765.12$23,818$2,587.47+$126.69MBPTSY
7$510,833,781$375,254,145.76$29,230$3,744.65+$510.80MBPTSY
8$1,960,465,947$1,413,873,800.93$36,816$5,540.38+$1960.43MBPTSY
9$7,168,849,807$5,071,151,244.70$47,806$8,413.17+$7168.80MBPTSY
10$25,001,243,986$17,330,574,692.45$64,324$13,170.85+$25001.18MBPTSY

BPTSY vs EPRT: Complete Analysis 2026

BPTSYStock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTSY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BPTSY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTSY vs SCHDBPTSY vs JEPIBPTSY vs OBPTSY vs KOBPTSY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.